Hexagon Publishes the Annual Report and Sustainability Report 2019
NACKA STRAND, Sweden, April 3, 2020 /PRNewswire/ -- Hexagon's Annual Report 2019 and separate Sustainability Report is now available at Hexagon's website hexagon.com. Hexagon intends to solely distribute the reports digitally. If you however still want to receive a printed copy of the Annual Report, please contact Hexagon at [email protected] or call +46-(0)8-601-26-28.
As previously communicated, Hexagon's Annual General Meeting will be held at 17:00 CET, 29 April 2020, at City Conference Center Stockholm (Norra Latin), Drottninggatan 71 B, Stockholm, Sweden. Notification of attendance must be made on 23 April 2020 at the latest. Due to the uncertainty regarding the spread of the coronavirus (Covid-19), precautions will be taken. The AGM will be held as short as possible and registration will commence at 16:30 CET. No food will be served.
This information is information that Hexagon AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 08:00 CET on 3 April 2020.
For further information please contact:
Maria Luthström Head of Investor Relations Hexagon AB +46-8-601-26-27 [email protected]
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor...
NOVA LEAP HEALTH CORP. ("Nova Leap" or "the Company"), a growing home health care organization, is pleased to announce that it has executed a definitive agreement (the "Agreement"), dated April 25, 2024, to acquire a home care services company ("the...
Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya's Scientific Advisory...
Adyton Resources Corporation announces that it has filed its financial statements for the three and twelve months ended December 31, 2023 and accompanying Management Discussion and Analysis on its SEDAR profile at www.sedar.com. ...
Gilead Sciences, Inc. today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide...
The "Global Men's Health and Wellness Market: Analysis By Type, By Distribution Channel, By Region Size & Forecast with Impact Analysis of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's offering.
In 2023, the...
